Good morning :)
Place Order
Add to Watchlist

EVOQ Remedies Ltd

EVOQ

EVOQ Remedies Ltd

EVOQ
Health CarePharmaceuticals
SmallcapWith a market cap of ₹19 cr, stock is ranked 4,203
High RiskStock is 4.29x as volatile as Nifty
7.990.00% (+0.00)
7.990.00% (+0.00)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CarePharmaceuticals
SmallcapWith a market cap of ₹19 cr, stock is ranked 4,203
High RiskStock is 4.29x as volatile as Nifty

How to use scorecard? Learn more

Health CarePharmaceuticals
SmallcapWith a market cap of ₹19 cr, stock is ranked 4,203
High RiskStock is 4.29x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
0.79
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
51.706.650.52%

Forecast & Ratings

Detailed Forecast 
Forecast data is currently unavailable for this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

EVOQ Remedies Limited is engaged in the pharmaceutical business. The Company is engaged in marketing, trading, and distribution of pharmaceutical formulation products such as anti-biotic drugs, anti-malarial drugs, anti-allergic and anti-cold drugs, analgesic/ antipyretic and anti-inflammatory drugs, dermatology products, cerebral activator drugs, neurological drugs, gastrointestinal drugs, steroids, gynecology drugs, calcium, multivitamins, antioxidants, and injections. The Company also deals in the trading of active pharmaceutical ingredients (APIs). The Company's products include Abacavir Sulphate, Acetazolamide, Acyclovir, Adefovir Dipivoxil Allylestrenole, Alpha Beta Arteether, Alpha Lipoic Acid, Alprazolam, Amisulpride, Amoxycillin Trihydrate, Ampicillin Trihydrate, Artemether, Atracurium Besylate, Azathioprine, Azithromycin, Balofloxacin, Bendamustine, Biotin, Bosentan, Brimonidine, Bezafibrate Mupirocin, Mycophenolate, Mycophenolate, Nadifloxacin, Naltrexone HCL and more.

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Income

Balance Sheet

Cash Flow

Income Statement

Industry refers to the sub-sector this company belongs to.

Higher than Industry Revenue Growth

A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 14.19%, vs industry avg of 9.04%

Constant Market Share

Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share stayed at 0%

Higher than Industry Net Income

Net income is equal to net earnings (profit) less expenses. This number is an important measure of how profitable the company is

Over the last 5 years, net income has grown at a yearly rate of 114.11%, vs industry avg of 15.28%

Loading...

Financial YearFY 2019FY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue3.259.0710.0216.7826.416.31
Raw Materialssubtract3.269.087.9414.4120.582.65
Power & Fuel Costsubtract0.000.000.030.010.050.01
Employee Costsubtract0.000.010.010.180.200.08
Selling & Administrative Expensessubtract0.010.011.161.324.503.98
Operating & Other expensessubtract-0.03-0.03-0.07-0.59-1.21-1.03
Depreciation/Amortizationsubtract0.000.000.000.000.000.01
Interest & Other Itemssubtract0.000.000.000.000.000.00
Taxes & Other Itemssubtract0.000.000.240.370.670.16
EPS0.140.0010.001.511.190.33
DPS0.000.000.000.000.000.00
Payout ratio0.000.000.000.000.000.00

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange

Peers & Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
EVOQ Remedies Ltd44.210.79
Sun Pharmaceutical Industries Ltd45.466.490.74%
Mankind Pharma Ltd64.6712.92
Cipla Ltd28.924.450.88%

Price Comparison

Compare EVOQ with any stock or ETF
Compare EVOQ with any stock or ETF
EVOQ
Loading...

Shareholdings

Promoter Holdings Trend

Decreased Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has decreased by 9.32%

Low Pledged Promoter Holding

Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Institutional Holdings Trend

Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding11.21%0.00%0.00%0.00%88.79%

Sep 2023

Mar 2024

Jun 2024

Sep 2024

Shareholding History

SepMarSepMarJunSep0.00%0.00%0.00%0.00%0.00%0.00%

Insider Trades & Bulk Deals

Loading...

smallcases

Looks like this stock is not in any smallcase yet.

Events

Dividend Trend

No Dividends

Dividends are the portion of earnings that a company distributes to all its shareholders every year

EVOQ has not given any dividends in last 5 years

Dividends

Corp. Actions

Announcements

Legal Orders

Dividends

Hmm, looks like data is unavailable here. Please come back after some time
News & Opinions
Corporate
Evoq Remedies to convene AGM

Evoq Remedies announced that the Annual General Meeting (AGM) of the company will be held on 28 September 2024.Powered by Capital Market - Live

3 months agoCapital Market - Live